Mr Mrs Miss Ms Dr Other

Dr
Thomas
Olbrich

Patent Director

Newcastle Office

Technology & Engineering

Telephone. +44(0) 191 205 8360
Mobile. +44(0) 771 744 0324
Email. tolbrich@hgf.com
Vcard
Linkedin

Experience

Tom is a PHD physicist with a real passion for most technologies and innovation. Tom's extensive experience covers a wide spectrum of technologies, from relatively simple concepts, such as shoes, floating platforms and power tools, to semiconductor and superconductor systems, as well as, computer implemented applications and medical devices. Tom has considerable experience (15+ years) in patent drafting and European, as well as worldwide patent prosecution.

Tom's areas of expertise include engineering, electronics and physics related technology in general, and in particular, medical devices, sporting goods, semiconductors and ICs, power tools, automotive fasteners, appliances, as well as, offshore and oil & gas technology (e.g. downhole tools, seismic interpretation software).

After spending a few years in the special military forces in his native Germany, competing i.a. in athletics, biathlon and bobsleigh, Tom went to study Applied Physics (MSc) at the University of Applied Science in Munich and Physics (BSc) at Nottingham Trent University. In order to further his studies, he then completed a PhD in Medical Physics at the University of Newcastle upon Tyne.

In 2005, he began working towards becoming a Patent and Trade Mark attorney. He has since gained extensive experience working with four leading European patent firms. He is known for a very personal approach and a high quality of work.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Europe

BSC

Physics

MSC

Applied Physics

PHD

Medical Physics

Publications

Northern Insight Article

View publication online

CSR

Tom is involved with mentoring Trainees in patent drafting.

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us